Latest stories on MPLT
MapLight Therapeutics files to sell 13.18M shares of common stock for holders
The Fly28 · bearishgeneral
MapLight Therapeutics to Participate in Upcoming Investor Conference
GlobeNewswire56 · neutralgeneral
MapLight Therapeutics to Participate in Upcoming Investor Conference
StockTitan56 · neutralgeneral
Needham cuts MapLight Therapeutics price target on dilution concerns
Investing.com Analyst Ratings34 · bearishanalyst
MapLight Therapeutics price target lowered to $43 from $45 at Needham
The Fly34 · bearishanalyst
MapLight Therapeutics announces $150M private placement
The Fly24 · bearishgeneral
MapLight Therapeutics reports Q2 EPS ($1.32), consensus ($1.31)
The Fly51 · neutralearnings
MapLight Therapeutics price target lowered to $31 from $35 at Raymond James
The Fly38 · neutralanalyst
MapLight Therapeutics, Inc. GAAP EPS of -$1.32 misses by $0.01
Seeking Alpha34 · bearishearnings
MapLight Therapeutics, Inc. (MPLT) files 8-K
SEC 8-K50 · neutralgeneral
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Insider67 · bullishproduct/pr
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire67 · bullishproduct/pr
Why is MapLight Therapeutics stock rallying today?
Investing.com Markets50 · neutralgeneral
MapLight Therapeutics secures $150M in PIPE funding
Seeking Alpha24 · bearishgeneral
MapLight Therapeutics stock jumps on $150M private placement
Investing.com Markets24 · bearishgeneral
MapLight Therapeutics Announces $150 Million Private Placement Financing
Business Insider28 · bearishgeneral
MapLight Therapeutics Announces $150 Million Private Placement Financing
GlobeNewswire24 · bearishgeneral
Maplight Therapeutics Downgraded To Neutral From Buy At Ubs Thefly News 2
The Fly42 · neutralanalyst
Maplight Therapeutics Downgraded To Neutral From Buy At Ubs
The Fly48 · neutralanalyst
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
PR Newswire50 · neutralgeneral
BMO cuts MapLight Therapeutics price target on trial results
Investing.com Analyst Ratings34 · bearishanalyst
Canaccord cuts MapLight Therapeutics stock price target on trial data
Investing.com Analyst Ratings38 · neutralanalyst
H.C. Wainwright cuts MapLight Therapeutics stock price target on trial results
Investing.com Analyst Ratings38 · neutralanalyst
MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia - Slideshow
Seeking Alpha50 · neutralgeneral
MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose
Stocktwits News22 · bearishearnings